FrancophonIA/ELRC3.0 huggingface dataset:
English: Staff 11 Staff in active employment 13 Duty travel 14 Socio-medical infrastructure 15 Exchange of civil servants and experts 16 Social welfare 17 Representation expenses 18 Staff insurances Total Title 1 Building/equipment 20 Investment in immovable property, renting of building and associated costs 21Expenditure on corporate data processing 12,499 4.7% 19,534 6.3% 18,023 5.6% 22 Movable property [..] 23 Other administrative expenditure 24 Postage 25 Expenditure on other meetings Total Title 2 Operational expenditure 300 Meetings 301 Evaluation of medicines 302 Translations 303 Studies and consultants 304 Publications 305 Community programmes 31Expenditure on business related IT projects 7,336 2.8% 14,223 4.6% 10,477 3.2% Total Title 3 TOTAL EXPENDITURE
Maltese: L-isforzi sabiex tiġi miġġielda l-AMR sejrin jibqgħu fuq quddiem nett fl-aġenda tal-Aġenzija u sejrin jinkludu l-appoġġ meħtieġ għal pjan ta' azzjoni talKummissjoni Ewropea, għall-inizjattivi transatlantiċi u tad-WHO, l-adozzjoni tal-approċċ 'saħħa waħda', l-iżvilupp jew l-aġġornament ta' linji gwida rilevanti (inkluż aspetti pedjatriċi) u l-ibbilanċjar tal-ħtieġa sabiex tiġi assigurata d-disponibbiltà kontinwa tal-antimikrobiċi fil-mediċini veterinarji bil-ħtieġa li jiġi minimizzat ir-riskju lill-bniedem mill-użu tagħhom fl-annimali.
English: The network has access to thousands of experts from Member States across Europe, allowing it to source the best possible expertise for the regulation of medicines in the European Union (EU).
Maltese: Innetwerk għandu aċċess għal eluf ta' esperti mill-Istati Membri fl-Ewropa kollha, li jippermettulu li jiġbor l-aqwa kompetenza possibbli għar-regolazzjoni ta' mediċini fl-Unjoni Ewropea (UE).
English: Develop an approach to systematically ensure quality control and data verification of product data in the common European database of veterinary medicinal products and link these data to adverse event information related to CAPs and non-CAPs in the Eudravigilance Veterinary data warehouse to allow signal detection in preparation for the new veterinary legislation Revise the reflection paper on promoting pharmacovigilance reporting to address adverse events in food-producing species Revise the surveillance strategy for centrally authorised products to link signal detection and PSURs and ensure better use of pharmacovigilance resources
Maltese: Żviluppi fl-industrija tal-farmaċewtika u n-numru ta' prodotti mediċinali fis-suq jinfluwenzaw b'mod qawwi l-volumi ta' attivitajiet ta' qabel lawtorizzazzjoni, applikazzjonijiet inizjali għat-tqegħid fis-suq u attivitajiet relatati fl-istadju ta' wara lawtorizzazzjoni.
English: − Eudra Common Directory (ECD), EU Controlled Terminology (EUTCT), EudraPharm for Human medicinal products, EudraPharm for veterinary medicinal products), Art 57 database (product database of EudraVigilance system) for storing master data;
Maltese: Fl-istess ħin, id-dehra tal-industrija tal-farmaċewtika qiegħda tevolvi, b'għadd dejjem jikber ta' intrapriżi żgħar jew ta' daqs medju (SMEs) iwettqu l-istadji bikrija tal-iżvilupp tal-mediċini.
English: Post Authorisation Measure data submissions Plasma Master File Annual update and variation applications
Maltese: L-Aġenzija hija organizzazzjoni mmexxija skont id-domanda.
English: Consolidate use of patients' preferences in benefit-risk assessment for initial marketing authorisation application Discuss with HTA bodies the use of and experience with the effects tables, identifying improvement opportunities Organise workshops to identify areas for improvement in the assessment reports and develop tool-kit for improvement of quality, consistency and robustness of benefit-risk assessments Develop and implement a specific benefit/risk guidance to support evaluation of biosimilar medicines
Maltese: Dan jinkludi l-iżvilupp u l-implimentazzjoni ta' oqfsa għal interazzjoni tal-partijiet ikkonċernati, l-identifikazzjoni tal-valuri tal-pazjenti u lpreferenzi fil-valutazzjoni tal-benefiċċji/riskji tal-mediċini, l-implimentazzjoni ta' seduti pubbliċi, ittwettiq ta' stħarriġ sabiex jinftiehmu aħjar u jkunu jistgħu jiġu sodisfatti l-ħtiġijiet u l-aspettattivi talpartijiet ikkonċeranti, u l-kooperazzjoni kontinwa ma' aġenziji oħra tal-UE fl-oqsma ta' interess komuni.
English: Activity statement: Oracle software licences, maintenance and support, training and training materials and specialised highlevel consultancy Objective: See Work programme 2016, heading 4 Budget: € 6.75 million over four years of which €500,000 operational and €6.25 million administrative Financial year: 2017-2020 Description of action: Inter-institutional negotiated procedure to be run by European Commission (DIGIT) for Oracle software licences, maintenance and support, training and training materials and specialised high-level consultancy Type of contract: European Commission tender procedure, Framework Contract implemented by Specific Contracts & Purchase Orders Number of contracts: 1 framework contract Indicative timeframe for contract: Commencing in 2017 Indicative timeframe for procurement:
Maltese: Bħala parti mill-appoġġ tax-xogħol tal-NCAs, l-Aġenzija sejra twassal sistemi telematiċi, kemm sabiex timplimenta r-rekwiżiti legali kif ukoll tgħin sabiex tilħaq eċċellenza operazzjonali, tiffaċilita l-bini tal-kapaċità permezz taċĊentru tat-Taħriġ tan-Netwerk, u tappoġġja l-kondiviżjoni tax-xogħol f'diversi oqsma.
English: Activity statement: Redaction review Clinical Data Policy 0070 Objective: See Work programme 2016, heading 1.6 Budget: € 1,000,000 over four years Financial year: 2016-2019 Description of action: Under supervision of EMA staff, undertake review of proposed redaction of commercial confidential information in a marketing authorisation application and review it against EMA redaction principles for acceptability, engage in correspondence thereon with the marketing authorisation holder using a justification table and via security communication system Type of contract: Framework contract implemented by Specific Contracts Number of contracts: 1 framework contract Indicative timeframe for contract: Commencing in 2016 Indicative timeframe for procurement:
Maltese: Fl-2016, l-Aġenzija sejra tibda tipprovdi appoġġ xjentifiku u regolatarju minn kmieni u mtejjeb lill-iżviluppaturi tal-mediċina permezz tal-iskema dwar il-mediċini ta' prijorità (PRIME).
English: Subtotal AST Total AST AST/SC1
Maltese: Intejbu l-kwalità u l-effiċjenza tal-ħidma regolatorja
English: Explore opportunities for peer review in later phases of the MAA review process and in case of substantial changes to the marketing authorisation Streamline and coordinate the clinical pharmacology support to centrally authorised products along their life-cycle Develop and improve guidance and provide internal training to ensure regulatory procedural consistency
Maltese: Id-disponibbiltà ta' għarfien espert sostenibbli, xjentifiku u regolatorju ta' kwalità għolja sejra tkun fattur kritiku ta' suċċess fl-indirizzar tal-progress fix-xjenza regolatorja.
English: Type I A variations
Maltese: Ammont ta' xogħol dejjem jevolvi
English: Develop with the FDA regulatory science approaches for paediatric diseases (including rare diseases), including finalise joint guidance document for Gaucher disease and formally implement TIGRE Establish Early interaction on paediatric development Conduct open regulatory sessions on Alzheimer's disease in academic settings, including a follow-up session at the ECNP congress Promote data-sharing from applicants with failed Alzheimer trials, in order to explore pitfalls and opportunities
Maltese: Għaldaqstant, l-oqsma tal-enfasi ewlenin tal-Aġenzija f'dan ir-rigward sejrin jinkludu l-utilizzazzjoni ta' għodod regolatorji eżistenti, bħall-awtorizzazzjoni kundizzjonali għat-tqegħid fis-suq u proċeduri ta' valutazzjoni aċċellerati, filwaqt li jinstabu modi sabiex jiġu ottimizzati l-mezzi ta' żvilupp u l-implimentazzjoni tal-iskema l-ġdida dwar il-mediċini ta' prijorità (PRIME).
English: Applications evaluated within legal timeframes Average assessment time for new active substances and biosimilars Average clock-stop for new active substances and biosimilars Labelling review of the English product information Annexes for new MAAs and line extensions by Day 10 and Day 140 of the evaluation process % of requests granted for accelerated assessment % of MAAs initiated under accelerated assessment that have been completed as accelerated assessment % of initial marketing authorisation applications (orphan/nonorphan/biosimilar) that had received centralised scientific advice
Maltese: Finalment, sejra tingħata attenzjoni partikolari sabiex jiġu indirizzati l-isfidi li jeżistu biex jitqiegħdu tilqimiet ġodda fis-suq u sabiex jiġi żgurat li tilqimiet awtorizzati huma disponibbli biex jiġu ttrattati b'mod rapidu inkursjonijiet ta' mard eżotiku, li r-riskju tiegħu żdied b'mod sostanzjali fi snin riċenti.
English: Q4 2013 Q2 2016 • Delivery of functionality required for mandatory use of the PSUR Repository eCTD 4 pre-project activities
Maltese: Diversi xogħlijiet ġodda bdew fl-2015 biss jew għad iridu jibdew.
English: Activity statement: Provision of information and communication technology advice, benchmarking and strategic consulting services: high level consultancy and studies Objective: See Work programme 2016, heading 4 Budget: € 3,000,000 over 4 years of which € 2 million operational and € 1 million administrative Financial year: 2014 - 2017/18 Description of action: High-level consultancy and studies are seen as provision of customised and individual, non-standard information for high-level and strategic issues Type of contract: European Commission tender procedure, Framework Contract implemented by Specific Contracts Number of contracts: 1 framework contract Indicative timeframe for contract: Commencing in 2017 Indicative timeframe for procurement:
Maltese: Hawnhekk, l-Aġenzija tkompli bil-kollaborazzjoni tagħha ma' awtoritajiet kompetenti u regolaturi mhux tal-UE sabiex iżżid id-dipendenza fuq l-ispezzjoni u l-attivitajiet ta' valutazzjoni ta' xulxin, tiżviluppa skambji ta' informazzjoni ta' prodotti tul iċ-ċiklu tal-ħajja tagħhom, tikkoopera dwar attivitajiet f'oqsma partikolari ta' interess, u tibni l-kapaċità u l-ħila tar-regolaturi f'pajjiżi b'sistemi anqas żviluppati.
English: Further information can be found on the Agency's website ema.europa.eu/medicines/EPAR/kiovig.
Maltese: Aktar informazzjoni tista' tinstab fis-sit elettroniku tal-Aġenzija ema.europa.eu/medicines/EPAR/kiovig.
English: Kiovig (human normal immunoglobulin)
Maltese: Kiovig (immunoglobulina normali umana)
English: Other information about Kiovig
Maltese: Informazzjoni oħra dwar Kiovig
English: Kiovig received a marketing authorisation valid throughout the EU on 19 January 2006.
Maltese: Kiovig irċieva awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fid-19 ta' Jannar 2006.
English: Kiovig was shown to be effective in PID, ITP and MMN.
Maltese: Kiovig wera li huwa effettiv fil-PID, l-ITP u l-MMN.
English: The medicine contains the active substance human normal immunoglobulin.
Maltese: Il-mediċina fiha s-sustanza attiva immunoglobulina normali umana.
English: The medicine is given by infusion (drip) into a vein.
Maltese: Il-mediċina tingħata permezz ta' infużjoni (dripp) ġol-vina.
English: • Patients with certain immune disorders.
Maltese: • Pazjenti b'ċerti disturbi immunoloġiċi.
English: These can be people who are born with a lack of antibodies (primary immunodeficiency syndrome, PID).
Maltese: Dawn jistgħu jkunu persuni mwielda b'nuqqas ta' antikorpi (sindrome tal-immunodefiċjenza primarja, PID).
English: These comprise patients with primary immune thrombocytopenia (ITP), who do not have enough platelets (components in the blood that help it to clot) and who are at high risk of bleeding; patients with Guillain-Barré syndrome or chronic inflammatory demyelinating polyneuropathy (CIDP), inflammatory disorders of the nerves that result in muscle weakness and numbness; patients with Kawasaki disease, a disease mainly seen in children which causes inflammation of blood vessels; and patients with multifocal motor neuropathy (MMN), nerve damage which causes weakness of the arms and legs.
Maltese: Dawn jinkludu pazjenti bi tromboċitopenija immunitarja primarja (ITP), li ma jkollhomx biżżejjed pjastrini (komponenti fid-demm li jgħinuh jagħqad) u li jkunu f'riskju għoli li jkollhom fsada; pazjenti li jbatu mis-sindrome Guillain-Barré jew polinewropatija demjelinata infjammatorja kronika (chronic inflammatory demyelinating polyneuropathy, (CIDP), disturbi infjammatorji tan-nervituri li jirriżultaw fi dgħjufija u tnemnim talmuskoli; pazjenti bil-marda Kawasaki, marda li tidher prinċipalment fit-tfal li tikkawża infjammazzjoni tal-vażi; u pazjenti b'newropatija motorja multifokali (multifocal motor neuropathy (MMN)), ħsara fin-nervituri li tikkawża dgħjufija fid-dirgħajn u fir-riġlejn.
English: The active substance in Kiovig, human normal immunoglobulin, is a highly purified protein extracted from human plasma (part of the blood).
Maltese: Is-sustanza attiva f'Kiovig, l-immunoglobulina normali umana, hija proteina ppurifikata ħafna li tiġi estratta mill-plażma (parti mid-demm) tal-bniedem.
English: As for all medicines, data on the use of Kiovig are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Kiovig hija ssorveljata kontinwament.
English: Kiovig was as effective as the standard treatment in preventing infections and reducing antibiotic use.
Maltese: Kiovig kien effettiv daqs il-kura standard għall-prevenzjoni ta' infezzjonijiet u għat-tnaqqis tal-użu tal-antibijotiċi.
English: The most common side effects with Kiovig (seen in more than 1 patient in 10) are headache, hypertension (high blood pressure), nausea (feeling sick), rash, tiredness, local reactions such as pain, swelling or itching at the site of injection, and fever.
Maltese: L-effetti sekondarji l-aktar komuni b'Kiovig (li dehru f'iktar minn pazjent 1 minn kull 10) huma wġigħ ta' ras, ipertensjoni (pressjoni tad-demm għolja), nawżja (tħossok ma tiflaħx), raxx, għeja, reazzjonijiet lokali bħal uġigħ, nefħa jew ħakk fis-sit tal-injezzjoni u deni.
English: Kiovig is a medicine used to support the immune system (the body's natural defences) in two main groups of patients:
Maltese: Kiovig huwa mediċina użata biex issostni s-sistema immunitarja (id-difiżi naturali tal-ġisem) f'żewġ gruppi ewlenin ta' pazjenti:
English: Kiovig must not be used in people who are hypersensitive (allergic) to human normal immunoglobulin or any of the other ingredients, or in patients who are allergic to other types of human immunoglobulin, especially where they have very low levels of immunoglobulin A (IgA) and they have antibodies against IgA.
Maltese: Kiovig m'għandux jintuża minn persuni li jkunu ipersensittivi (allerġiċi) għall-immunoglobulina normali umana jew għal kwalunkwe wieħed mill-ingredjenti l-oħra, jew f'pazjenti li jkunu allerġiċi għal tipi oħra ta' immunoglobulini umani, speċjalment meta jkollhom livelli baxxi ħafna ta' immunoglobulina A (IgA) u jkollhom antikorpi kontra l-IgA.
English: Kiovig was effective in maintaining muscle strength and reducing disability.
Maltese: Kiovig kien effettiv fiż-żamma tassaħħa tal-muskoli u fit-tnaqqis tad-diżabilità.
English: Kiovig works by restoring abnormally low IgG levels to their normal range in the blood.
Maltese: Kiovig jaħdem billi jreġġa' għan-normal il-livelli baxxi b'mod anormali tal-IgG fid-demm.
English: • Patients at risk of infection because they do not have enough antibodies (also called immunoglobulins, proteins in the blood that help the body to fight disease).
Maltese: • Pazjenti li huma f'riskju ta' infezzjoni minħabba li ma jkollhomx biżżejjed antikorpi (li jissejħu wkoll immunoglobulini, proteini fid-demm li jgħinu lill-ġisem biex jiġġieled il-mard).
English: The second study looked at using Kiovig to adjust the immune system in 23 patients with ITP.
Maltese: It-tieni studju eżamina l-użu ta' Kiovig biex jaġġusta s-sistema immunitarja fi 23 pazjent bl-ITP.
English: In the first study, Kiovig was used to replace antibodies in 22 patients with PID who had very low or no levels of immunoglobulin.
Maltese: Fl-ewwel studju, Kiovig intuża biex jissostitwixxi l-antikorpi fi 22 pazjent bil-PID u li kellhom livelli baxxi ħafna ta' immunoglobulina jew xejn.
English: Based on its effectiveness in these diseases, Kiovig can be approved for use in the treatment of other types of immunodeficiency, as well as low antibody levels due to Guillain-Barré syndrome, Kawasaki disease or CIPD, without the need for specific studies in these diseases.
Maltese: Abbażi tal-effikaċja tiegħu f'dan il-mard, Kiovig jista' jiġi approvat għall-użu fil-kura ta' tipi oħra ta' immunodefiċjenza, kif ukoll livelli baxxi ta' antikorpi minħabba s-sindrome Guillain-Barré, il-marda Kawasaki jew CIPD, mingħajr il-ħtieġa ta' studji speċifiċi f'dan il-mard.
English: How does Kiovig work?
Maltese: Kif jaħdem Kiovig?
English: These also include people who have developed a lack of antibodies after birth (secondary immunodeficiency syndrome, SID), who have low levels of certain antibodies (called IgG) and who suffer from infections that are severe, keep coming back, and are not cured by medicines used to treat infections;
Maltese: Dawn jinkludu wkoll persuni li żviluppaw nuqqas ta' antikorpi wara t-twelid (sindrome talimmunodefiċjenza sekondarja, SID), li jkollhom livelli baxxi ta' ċerti antikorpi (imsejħa IgG) u li jbatu minn infezzjonijiet li huma severi, jibqgħu jfeġġu, u ma jiġux ikkurati b'mediċini użati għallkura ta' infezzjonijiet;
English: At higher doses, it can help to adjust an abnormal immune system and modulate the immune response.
Maltese: F'dożi ogħla jista' jgħin fl-aġġustament ta' sistema immunitarja anormali u fil-modulazzjoni tar-reazzjoni immunoloġika.
English: The third and fourth studies were in a total of 28 patients with MMN.
Maltese: It-tielet u r-raba' studji saru fuq total ta' 28 pazjent li jbatu bl-MMN.
English: 3 x 28 film-coated tablets
Maltese: Flixkun (HDPE) 3 x 28 pillola miksija b'rita
English: 28 film-coated tablets
Maltese: Flixkun (HDPE) 28 pillola miksija b'rita
English: -- Each dose (2 ml) contains:
Maltese: --1 Kull doża (2 ml) fiha:
English: Porcine Parvovirus strain 27a VP2 subunit antigen ≥ 1.0 RP* * Relative Potency (ELISA)
Maltese: Antiġen subunità tal-parvovirus tal-qżieqeż razza 27a VP2 ≥ 1.0
English: EU number
Maltese: Numru tal-UE
English: Content
Maltese: Ippakkjar
English: Route of administration
Maltese: Amministra-zzjoni
English: EMA/279182/2014 EMEA/V/C/002761
Maltese: EMEA/V/C/002761
English: It contains a bacterial strain called R32E11.
Maltese: Fih razza batterika msejħa R32E11.
English: Other information about Eryseng:
Maltese: Informazzjoni oħra dwar Eryseng:
English: Eryseng contains an adjuvant (aluminium hydroxide, DEAE-dextran and ginseng) to enhance the immune response.
Maltese: Eryseng fih aġġuvant (aluminium hydroxide, DEAE-dextran u ginseng) biex itejjeb ir-rispons immunitarju.
English: The first laboratory study showed 90% (27 out of 30) of vaccinated pigs were protected against Erysipelothrix rhusiopathiae serotype 1 remaining free of specific skin lesions whilst 93% (28 out of 30) of vaccinated pigs were protected against Erysipelothrix rhusiopathiae serotype 2 remaining free of specific skin lesions.
Maltese: L-ewwel studju fil-laboratorju wera li 90% (27 minn 30) tal-majjali mlaqqma kienu protetti kontra Erysipelothrix rhusiopathiae serotip1 u baqgħu liberi minn leżjonijiet tal-ġilda speċifiċi filwaqt li 93% (28 minn 30) tal-majjali mlaqqma kienu protetti kontra Erysipelothrix rhusiopathiae serotip 2 u baqgħu liberi minn leżjonijiet tal-ġilda speċifiċi.
English: The second laboratory study showed 93% (14 out of 15) of pigs were protected against challenge with Erysipelothrix rhusiopathiae serotypes 1 and 2.
Maltese: It-tieni studju fil-laboratorju wera li 93% (14 minn 15) tal-majjali kienu protetti kontra sfida b'Erysipelothrix rhusiopathiae serotip 1 u 2.
English: In a laboratory study involving 40 pigs, 30 pigs were vaccinated with two doses, separated by three weeks, while a control group of 10 pigs received placebo (dummy treatment).
Maltese: Fi studju f'laboratorju li involva 40 majjal, 30 majjal ġew imlaqqma b'żewġ dożi, b'perjodu ta' tliet ġimgħat bejniethom, filwaqt li grupp ta' kontroll ta' 10 majjali rċieva plaċebo (trattament finta).
English: Swine erysipelas vaccine (inactivated)
Maltese: Vaċċin ta' erysipelas tal-majjali (inattivat)
English: Eryseng is used to protect male and female pigs against swine erysipelas caused by Erysipelothrix rhusiopathiae bacteria of specific types called serotype 1 and serotype 2.
Maltese: Eryseng jintuża biex jipproteġi majjali rġiel u nisa kontra erysipelas tal-majjali kkawżata mill-batterji Erysipelothrix rhusiopathiae ta' tipi speċifiċi msejħa serotip 1 u serotip 2.
English: Eryseng is a bacterial vaccine.
Maltese: Eryseng huwa vaċċin batteriku.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Eryseng on 4 July 2014.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Eryseng fl-4 ta' Lulju 2014.
English: Why has Eryseng been approved?
Maltese: Għaliex ġie approvat Eryseng?
English: All pigs were challenged 22 days after the second vaccination dose with injections of the bacteria Erysipelothrix rhusiopathiae serotypes 1 and 2.
Maltese: Ilmajjali kollha ġew sfidati 22 jum wara t-tieni doża ta' tilqim b'injezzjonijiet ta' batterju Erysipelothrix rhusiopathiae serotip 1 u 2.
English: Eryseng is available as a suspension for injection.
Maltese: Eryseng jiġi bħala sospenzjoni għal injezzjoni.
English: The benefit-risk balance may be found in the scientific discussion module of this EPAR.
Maltese: Il-bilanċ tal-benefiċċju-riskju jista' jinstab fil-modulu ta' diskussjoni xjentifika ta' dan l-EPAR.
English: What is the risk associated with Eryseng?
Maltese: X'riskji huma assoċjati ma' Eryseng?
English: This will help protect them against swine erysipelas.
Maltese: Dan se jgħin jipproteġihom kontra erysipelas tal-majjali.
English: Eryseng is a veterinary vaccine that contains inactivated (killed) Erysipelothrix rhusiopathiae bacteria.
Maltese: Eryseng huwa vaċċin veterinarju li fih il-batterju Erysipelothrix rhusiopathiae inattivat (maqtul).
English: How has Eryseng been studied?
Maltese: Kif ġie studjat Eryseng?
English: In the control group more than 80% of pigs showed specific skin lesions.
Maltese: Fil-grupp ta' kontroll aktar minn 80% tal-majjali wrew leżjonijiet tal-ġilda speċifiċi.
English: How does Eryseng work?
Maltese: X'inhu Eryseng?
English: The most common side effect (seen in more than 1 in 10 pigs) with Eryseng is mild to moderate inflammation at the injection site, which typically resolves within four days but in some cases may persist for up to 12 days post-vaccination.
Maltese: L-effett sekondarju l-aktar komuni (li deher f'iktar minn ħanżir 1 minn kull 10) b'Eryseng huwa infjammazzjoni ħafifa sa moderata fil-post tal-injezzjoni, li tipikament titlaq fi żmien erbat ijiem iżda f'xi każijiet tista' tibqa' għal 12-il jum wara t-tilqima.
English: Swine erysipelas is a bacterial disease of pigs characterised by sudden death, fever associated with diamond skin lesions, arthritis and by abortion in pregnant sows.
Maltese: Erysipelas tal-majjali hija marda batterika tal-majjali kkaratterizzata minn mewta għall-għarrieda, deni assoċjat ma' leżjonijiet tal-ġilda f'għamla ta' djamanti, artrite u ma' abort f'majjali nisa tqal.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Eryseng exceed the risks for the approved indication and recommended that Eryseng be given a marketing authorisation.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu Veterinarju (CVMP) ikkonkluda li l-benefiċċji ta' Eryseng huma akbar mir-riskji għall-indikazzjoni approvata u rrakkomanda li Eryseng jingħata awtorizzazzjoni għat-tqegħid fis-suq.